Clinical Trial: Phase II Clinical Trial of Interleukin-2 in AD
Study Status: Completed
Recruit Status: RECRUITING
Condition: Alzheimer Disease
Study Type: INTERVENTIONAL
Official Title: A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients With Mild to Moderate Alzheimer's Disease
Brief Summary:
Neuroinflammation is a significant component of Alzheimer disease (AD).Our group recently demonstrated that regulatory T cells (Tregs) have a compromised phenotype and reduced suppressive function in AD patients, skewing the immune system toward a proinflammatory status and potentially contributing to disease progression.Low dose interleukin-2 (IL-2) is now viewed as a promising immunoregulatory drug with the capacity to selectively expand and restore functional Tregs.This study is a phase II, randomized,…
Read more